NHS England Approves Life-Extending Breast Cancer Drug Enhertu Following Years of Campaigning

Patients living with an incurable form of advanced breast cancer in England can now receive the life-prolonging medication Enhertu on the NHS. The decision marks the end of a protracted two-year standoff between healthcare regulators and drug manufacturers over the treatment's cost-effectiveness.

Clinical trial evidence shows that Enhertu can provide patients with an average of almost seven additional months of life, with some individuals surviving up to three years longer. The drug is targeted at women suffering from HER2-low metastatic breast cancer, a condition where the disease has spread to other parts of the body. Healthcare authorities estimate that the newly approved access will benefit approximately 1,000 patients across England each year.

The policy change took effect on Thursday, permitting clinicians across England to immediately begin prescribing the therapy. Health authorities in Wales are anticipated to follow the decision shortly, although the updated guidance will not automatically take effect in Northern Ireland. The development brings England into closer alignment with Scotland, which cleared the drug for NHS usage in 2023, as well as 26 other nations across Europe where patients have already been receiving it.

Welcoming the move, Health Secretary Yvette Cooper emphasized the significant impact the medication would have on families affected by the disease. She described Enhertu as potentially life-changing and noted that its availability on the NHS serves as a direct tribute to the relentless determination of charities and grassroots advocates who continued to lobby for access despite earlier rejections.

Despite the widespread relief, patient groups have underscored the heavy emotional and human toll caused by the years of administrative delay. The charity Breast Cancer Now noted that while the persistent efforts of campaigners had finally succeeded, thousands of individuals had been unable to obtain the drug during the intervening period, with many dying before the policy was reversed.

Claire Rowney, chief executive of Breast Cancer Now, expressed mixed emotions over the outcome. While describing the announcement as a momentous milestone, she cautioned that the celebration must be tempered by the memory of the devastating cost of delay. She called on the government, the National Institute for Health and Care Excellence (NICE), NHS England, and the pharmaceutical industry to reform what she characterized as a broken appraisal system, ensuring that patients with terminal conditions are not forced to spend their remaining time campaigning for vital care.

Among those directly affected by the ruling is Kate Wills, 51, who lives with stage-four HER2-low metastatic breast cancer that has spread to her bones and lungs. Despite managing a demanding professional career, raising a family, and projecting an active, happy life on social media, she previously endured the painful reality of knowing an effective treatment existed that she could not access through the state health system.

Upon learning that the NHS had sanctioned the medication, Wills reacted with tears of relief, describing the news as an enormous source of hope. For those living with terminal illness, maintaining optimism can be exceptionally challenging, and she explained that having access to Enhertu has allowed her to expand her personal horizons. Where she once focused solely on living long enough to see her youngest child complete school, she now dares to dream about watching her children fall in love and get married.

However, Wills described the triumph as profoundly bittersweet, as her immediate thoughts turned toward the friends and fellow advocates who were unable to receive the medication in time. Many women who stood alongside her in the fight for approval lost their lives while waiting for health officials and pharmaceutical executives to reach a consensus.

One such advocate was Jeannie Ambrose, who spoke publicly two years ago at the age of 53 about her desire to live and spend her remaining time with family rather than being forced to campaign for her life. Ambrose died in January of this year. Reflecting on her late friend, Wills stated that Ambrose would have been overjoyed by the approval, but equally angry about the extensive delay and the sense of rejection patients experienced during the process.

The eventual approval of Enhertu did not stem from major price reductions by the pharmaceutical companies behind the drug, Daiichi Sankyo and AstraZeneca. BBC reporting indicates that the manufacturers did not substantially reduce their asking price from when the drug was initially rejected as poor value for money by NICE in 2024.

Instead, the policy reversal was largely unlocked by a broader international trade agreement with the United States, under which the UK government committed to increasing overall spending on pharmaceuticals by 25 percent. This strategic shift prompted NICE to adjust its economic assessment thresholds for new medical treatments.

As part of these revisions, NICE increased the maximum amount the NHS is permitted to spend per Quality-Adjusted Life Year (QALY)—a measure evaluating the cost of granting a patient an additional year of good-quality life. The upper limit for a QALY was raised from £30,000 to £35,000. Furthermore, in late August, the regulatory body implemented a more nuanced methodology for evaluating patient quality of life, which collectively tilted the appraisal balance in favor of Enhertu.

Following the announcement, AstraZeneca welcomed the decision by NICE while emphasizing the need for ongoing collaboration across the entire healthcare ecosystem to facilitate faster and more equitable access to innovative treatments in the future. Meanwhile, Helen Knight, director of medicines evaluation at NICE, expressed satisfaction that a workable commercial solution had ultimately been secured to deliver the treatment to patients.